HOLX

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024

Retrieved on: 
Tuesday, April 2, 2024
General Health, Health Technology, Health, Medical Devices, Hologic, HOLX

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes.
  • In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
  • Interested participants may listen to the call by dialing (888) 256-1007 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 7680382.
  • Hologic will provide a live and webcast replay of the call on the Company’s website at www.investors.hologic.com .

Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Health, Consumer, Women, Health Technology, Research, Science, Breast cancer, Woman, Recurrence, HOLX, BCI, Physician, HR, Cancer, Risk, Doctor of Philosophy, Yale School of Medicine, YES, Associate, Patient, National Comprehensive Cancer Network, Yale school, Diagnosis, Pharmaceutical industry

The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.

Key Points: 
  • The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.
  • Undertreatment: The remaining 37% of changes in treatment decisions by physicians were from a NO to a YES recommendation for extended anti-estrogen therapy.
  • “These results further reinforce the impact of the Breast Cancer Index test in clinical practice.
  • “As more research is published, I’m thrilled to see the continued, impressive utility of the Breast Cancer Index test.

Hologic to Unveil Groundbreaking AI Research at ECR 2024

Retrieved on: 
Tuesday, February 27, 2024
Other Health, Software, Research, Radiology, Oncology, Medical Devices, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Health, Breast cancer, Algorithm, Artificial intelligence, AI, Education, HOLX, CEM, European, Cancer, Genius, Northwestern Memorial Hospital, Business, CAD, Medical imaging, ECR, Sittard-Geleen, Mammography, Bayer, Associate, Congress, Machine learning, Breast imaging, Workflow

The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists.

Key Points: 
  • The pioneer behind 3D mammography, Hologic will present new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists.
  • “Beyond its impact on our daily practices, these data emphasize the transformative potential AI has to drive improvements across the breast health spectrum.
  • “We’re excited to present groundbreaking research at ECR and to continue our collaboration with Bayer on contrast-enhanced mammography.
  • Hologic’s Genius AI® Detection technology is a cutting-edge solution now commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024.

Hologic to Webcast Presentations at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Medical Devices, Health, Consumer, Surgery, Women, Health Technology, Conference, Hologic, HOLX, Cryptocurrency

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
    Raymond James' 45th Annual Institutional Investors Conference on Monday, March 4 at 8:40 a.m. Eastern Time (ET).
  • Needham Virtual Healthcare Conference on Tuesday, April 9 at 11:45 a.m.
  • Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com .
  • The webcasts will be available for 30 days following each event.

Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Technology, FDA, Other Health, Health, Women, Oncology, Health Technology, Medical Devices, Artificial Intelligence, Consumer, Multimedia, Cell, Breast cancer, Marie Cassidy, American Cancer Society, 3D, Patient, Laboratory, Artificial intelligence, Cervical cancer, HOLX, Food, PAP, Disease, Acquisition, OB, Woman, Medical device

“Our technologies have had a tremendous impact on decreasing cancer rates in women, and we are incredibly excited by the promise of Genius Digital Diagnostics.

Key Points: 
  • “Our technologies have had a tremendous impact on decreasing cancer rates in women, and we are incredibly excited by the promise of Genius Digital Diagnostics.
  • With the Genius Digital Diagnostics System, the glass slides are digitally imaged and an artificial intelligence algorithm is applied to pinpoint the cells that cytologists and pathologists should review.
  • The Genius Digital Diagnostics System also offers the opportunity for greater collaboration across lab and other healthcare settings.
  • The Genius Digital Diagnostics System is already commercially available in Europe, Australia and New Zealand.

Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes

Retrieved on: 
Tuesday, January 16, 2024
Women, Medical Supplies, Oncology, General Health, Health, Medical Devices, Health Technology, Consumer, Ageing, Diabetes, Mortality, Woman, Death, Infertility, Sadness, Multimedia, Sustainable Development Goals, UN, Walking, Democratic republic, Stroke, Pain, Risk, Safety, COVID-19, HOLX, Emotion, Congo, United Nations, Infection, United, Gallup, Birth control

The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.

Key Points: 
  • The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.
  • The Index also shows that more women are sad, angry and worried now than at the height of the pandemic.
  • The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide.
  • Investing in women’s health not only benefits individual women, but also their families, communities and economies.”
    Key findings from this year’s Index:
    Testing for major health conditions remains low.

Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women

Retrieved on: 
Thursday, January 11, 2024
Oncology, Health, Consumer, Women, Surgery, Health Technology, General Health, Hologic, AUB, Woman, Patient, Uterine fibroid, MD, Pelvic pain, Life, Multimedia, Fibroid, HOLX, Pain, Better, Bleeding, Hysterectomy, Fatigue, Marketing, Physician, Birth control

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™.
  • Launching in New York, Los Angeles, Atlanta and Detroit, the campaign seeks to increase awareness about daily quality-of-life challenges such as heavy and disruptive periods, pelvic pain and fibroids, while also educating women about available treatment options.
  • The campaign hub, BetterIsPossible.com , offers downloadable materials such as a period symptom quiz, discussion guides and information about potential treatment options.
  • For more information about how Hologic is supporting physicians to discuss hysterectomy-alternative treatment options, visit gynsurgicalsolutions.com/hcp/for-medical-professionals/
    For more information about the Better is Possible campaign and to access educational resources, visit BetterIsPossible.com .

Hologic to Announce Financial Results for the First Quarter of Fiscal 2024 on Thursday, February 1, 2024

Retrieved on: 
Thursday, January 4, 2024
Oncology, Medical Devices, Health, Health Technology, Other Health, Biotechnology, HOLX, Hologic

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes.
  • In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
  • Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5909239.
  • Hologic will provide a live and webcast replay of the call on the Company’s website at https://investors.hologic.com .

Hologic to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Oncology, Medical Devices, Health, Other Health, General Health, Biotechnology, HOLX, Q&A, Conference, Hologic

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time.
  • The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com .
  • The webcast will be available for 30 days following the event.

KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation

Retrieved on: 
Thursday, November 30, 2023
Finance, Medical Devices, Health, Professional Services, Health Technology, Breast, Investment, KKR, Prostate Cancer Foundation, Lung cancer, HOLX, Partnership, Growth, Biopsy, Medical imaging, Hologic

KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator.

Key Points: 
  • KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator.
  • The new platform, named Maverix Medical, will be managed by Ajax Health under the leadership of Duke Rohlen.
  • Maverix will develop and acquire innovative technologies and commercial operations within the lung cancer disease category.
  • Each year, more people die of lung cancer than of colon, breast and prostate cancers combined.1
    KKR and Ajax Health will contribute existing portfolio company Serpex Medical to the platform.